" "

Due to COVID-19, HCA’s lobby is closed. Learn more about your customer service options.

Prescription drug price transparency

Want to stay up-to-date on prescription drug price transparency?

Sign up for notifications

Program updates

January 1, 2021 update

The Health Care Authority (HCA) has created a status report detailing the current state of the program as the agency begins to receive drug pricing and cost data from health carriers, pharmacy benefit managers (PBM), drug manufacturers and pharmacy service administrative organizations (PSAO).

October 15, 2020 update

HCA plans second phase rulemaking under RCW 43.71C

HCA is dedicated to working with reporting entities to ensure successful implementation of a Drug Price Transparency reporting program under RCW 43.71C. We are grateful for all input received thus far and remain committed to collaboration with our stakeholders. 

Accordingly, HCA will be launching a second phase of rulemaking with an anticipated CR-101 filing next week. The rulemaking will:

  • Amend WAC 182-51-0600(2)(b) to clarify that manufacturers must report new covered drugs within 30 days after  release to the market instead of prior  to their release. In the meantime, HCA will not initiate enforcement under RCW 43.71C.090 for manufacturers who do not report the information required by RCW 43.71C.050 prior to the release of a new covered drug to the market. 
  • Amend or create a new rule containing the contents of the nondisclosure agreement.

Reporting entity notifications

The table below highlights major milestone communications sent to reporting entities. It is not a comprehensive list of communications sent.


Notification topic and audience


Notification to PBMs: DPT data submission guide and templates updated and posted


Notification to manufacturers: submission guide finalized


Critical update: notification to all submitter types of change to support email inboxes


Notification to PBMs: submission deadline postponed


Notification to PBMs: submission guide ready


Notification to manufacturers: submission guide finalized


Notification to carriers: submission guide finalized


Notification to manufacturers: submission guide updated


Notification to reporting entities: carrier and PSAO submission guides updated


Notification to PBMs: reminder reminder of reporting requirement and draft PBM submission guide

10/28/2020 Drug Price Transparency data submission FAQ sent to all reporting entities

Seventh letter to PBMs: draft PBM submission guide ready for review and feedback; reminder to register


Sixth letter to reporting entities: data submission guides ready for manufacturers, carriers, and PSAOs; reminder to register


Fifth letter to manufacturers: notification of data submission guide ready and a reminder to register


Fourth letter to reporting entities: notification of data submission guide ready and a reminder to register


Third letter to reporting entities: draft data submission guide and reminder to register


Reminder letter to reporting entities: data definitions review and reminder to register


Second letter to reporting entities: data definitions review and reminder to register


Introductory letter to reporting entities: registration instructions

Reporting entity resources

The following resources are for reporting entities who may need assistance.

The excel templates below are available as an aid if you are hand-keying data for submissions to the Drug Price Transparency program. These workbooks are programmed with simple rules that will help you avoid some common errors that can occur.

Important note about Excel version: We recommend using Microsoft Excel 2016 or earlier for the submission guides. Using Microsoft Excel 2019 can cause formatting issues when saving as a CSV file.



Effective 12/22/2020


Effective  3/22/2021

Pharmacy Benefit Managers (PBMs)

Effective on 4/30/2021

Pharmacy Services Administrative Organizations (PSAOs)

Effective 12/10/2020

Stakeholder meetings

At each meeting, HCA will give a short overview of Chapter 43.71C RCW then use the majority of time to take questions and hear concerns from stakeholders. We will focus on a different supplier in each meeting. The public is invited to participate in any of the meetings.

Meeting schedule

Date and time Meeting type Materials
February 26, 2020
2:30-4 p.m.
Manufacturer reporting

Slide deck (02/26/20)

Recorded webinar (02/26/20)

April 1, 2020
1-2:30 p.m.

Issuer / carrier reporting

Webinar only, no in person meeting due to COVID-19

 Updated slide deck (04/01/20)

Recorded webinar (04/01/2020)

April 29, 2020
2:30-4 p.m.

Pharmacy benefit manager / pharmacy service administrative organization reporting

Webinar only, no in person meeting due to COVID-19

Slide deck (04/29/2020)

Recorded webinar (04/29/2020)


In 2019, the Washington State Legislature passed Engrossed Second Substitute House Bill into law. This law states requires issuers of health insurance, pharmacy benefit managers (PBMs), manufacturers, and pharmacy service administrative organizations (PSAOs) to submit data to the Health Care Authority (HCA). The purpose is to create an annual report on how prescription drugs affect health care costs. The law also requires pharmaceutical manufacturers to submit data to HCA relating the new drug applications (NDA).